Phase 2 Autism Spectrum Disorder Trial, Recruiting NCT05546554 Sponsor: Stanford University Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Phase 2 Autism Spectrum Disorder Trial, Recruiting

NCT05546554
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 13 and 17 years old and are being seen as an outpatient (not currently admitted to a hospital).
  • You have been diagnosed with Autism Spectrum Disorder (ASD), confirmed through specific standard diagnostic tools used by clinicians.
  • You are male or female.
  • You have sleep problem data available from a sleep study (done in a lab) and/or a wrist-worn sleep tracking device.
  • You have sleep difficulties, such as poor sleep quality, sleeping less than 7 hours, or waking up for more than 30 minutes during the night, as measured by specific sleep assessments.
  • You have a caregiver who can reliably bring you to appointments, give accurate feedback about you, and sees you regularly.
  • Any medications you take have been at a stable dose for at least 2 weeks (or at least 4 weeks if you take Prozac/fluoxetine).
  • No changes to your current treatments or therapies are planned during the trial.
  • You are willing to provide saliva samples, attend safety check-ins at every visit, complete sleep lab studies at weeks 4 and 8, and wear a sleep-tracking watch for 2 weeks before and throughout the 8-week trial.
  • If you are female, sexually active, and able to become pregnant, you are willing to use two forms of contraception at the same time (one hormonal, one barrier method such as a condom).

Who may not be able to join:

  • You are currently having thoughts of suicide, or have been diagnosed with severe depression, a substance use disorder, schizophrenia, schizoaffective disorder, or a psychotic disorder.
  • You have unstable health conditions such as migraines, asthma, a seizure disorder, serious liver, kidney, or heart problems, a severe allergic condition (such as anaphylaxis), obstructive sleep apnea, or severe liver failure.
  • There is evidence that your autism may be caused by a metabolic or infectious condition, based on your medical history or test results.
  • You are pregnant, or you are a sexually active female who is not using a reliable form of contraception (pregnancy tests will be used in this study).
  • You currently take certain medications including benzodiazepines, anti-epileptic drugs prescribed specifically for seizures/epilepsy, melatonin, or antihistamines that affect the brain.
  • You have ever had an allergic reaction to the study drug, suvorexant.
  • You have previously had severe side effects from suvorexant.
  • You have already had a full, adequate course of treatment with suvorexant.
  • You currently take medications known to interact with suvorexant, such as those that affect a liver enzyme called CYP3A (confirm with trial site).
  • You have a history of narcolepsy (a condition causing sudden, uncontrollable sleep attacks).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Antonio Y. Hardan, MD, Stanford University

Phone: (650) 736-1235

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
9 August 2023
Est. completion
28 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in sleep architecture as measured by polysomnography (PSG) and/or actigraphy, examples include sleep latency and non-rapid eye movement (NREM)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov